Refractory Tumors — Phase I Safety Study of DMXAA in Refractory Tumors
Citation(s)
5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.